Publicaciones (184) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer

    Breast Cancer Research, Vol. 26, Núm. 1

  2. A randomized controlled trial of the effectiveness of a one-to-one peer support intervention on resilience, social support, and salivary cortisol in recently diagnosed women with breast cancer

    European Journal of Oncology Nursing, Vol. 71

  3. Acetyl-CoA carboxylase 1 controls a lipid droplet–peroxisome axis and is a vulnerability of endocrine-resistant eR+ breast cancer

    Science Translational Medicine, Vol. 16, Núm. 736

  4. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  5. Müllerian adenosarcoma with sarcomatous overgrowth and heterologous elements: A case report and literature review

    Revista Espanola de Patologia, Vol. 57, Núm. 3, pp. 176-181

  6. Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

    ESMO Open, Vol. 9, Núm. 10

  7. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  8. Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

    Breast, Vol. 77

  9. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

  10. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2023

  1. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma

    British Journal of Cancer, Vol. 129, Núm. 5, pp. 811-818

  2. Ariketa fisikoa hirugarren adineko pertsonetan

    Osagaiz: osasun-zientzien aldizkaria, Vol. 7, Núm. 1, pp. 87-88

  3. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778

  4. Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature

    Frontiers in Immunology, Vol. 14

  5. Early Detection of Brain Metastases in a Supervised Exercise Program for Patients with Advanced Breast Cancer: A Case Report

    Medicine and science in sports and exercise, Vol. 55, Núm. 10, pp. 1745-1749

  6. Efectividad del debate universitario guiado en la conciencia de género y legitimación del dolor hacia el o la paciente: estudio pre-post

    Innovación docente e investigación en salud: nuevas tendencias para el cambio en la enseñanza superior (Dykinson), pp. 223-230

  7. Evaluating gender awareness, gender-related health knowledge and patient pain legitimation among nursing students: A quasi-experimental study

    Nurse Education in Practice, Vol. 72

  8. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2561-2570

  9. Germline gain-of-function MMP11 variant results in an aggressive form of colorectal cancer

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 283-297

  10. Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

    Nature Communications, Vol. 14, Núm. 1